Unicycive Therapeutics Faces Securities Fraud Lawsuit
Investors who lost money in Unicycive Therapeutics are being offered the opportunity to lead a securities fraud class action lawsuit. The complaint alleges misleading statements regarding the company's manufacturing practices.
Glancy Prongay Wolke & Rotter LLP has announced that investors who sustained losses in Unicycive Therapeutics, Inc. (Nasdaq: UNCY) have an opportunity to lead a securities fraud class action lawsuit. The lawsuit, filed on behalf of investors who purchased or acquired Unicycive securities between December 29, 2025, and June 29, 2026, alleges that the company and its executives made materially false and misleading statements.
The complaint asserts that Unicycive failed to disclose crucial information regarding its third-party manufacturing vendor. Specifically, the company allegedly did not inspect the vendor's facility for compliance with current good manufacturing practices (cGMP) and lacked a reasonable basis to believe the vendor had resolved deficiencies cited by the U.S. Food and Drug Administration (FDA). This created an undisclosed risk of delays in regulatory approval for the company's drug OLC.
According to the lawsuit, these alleged failures and misrepresentations led to a reasonable likelihood of delays in the regulatory approval of OLC. Consequently, the complaint argues that Unicycive's positive statements about its business, operations, and prospects were materially misleading and lacked a reasonable basis. The deadline for investors to seek to be appointed lead plaintiff is November 2, 2026.
Glancy Prongay Wolke & Rotter LLP, a law firm specializing in shareholder rights litigation, is encouraging affected investors to come forward. The firm notes that no class has yet been certified in the action, and investors can choose to participate or remain absent class members.